Study on diagnosing and managing hereditary angioedema in Egypt
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at how people with hereditary angioedema (HAE) are diagnosed and treated in Egypt. It may help doctors better understand and care for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of HAE type 1 or type 2 (based on your medical history or lab tests).
- For the first part of the study, you were diagnosed or treated between January 2015 and August 2025.
- For the second part, you have a doctor-confirmed diagnosis and have signed a consent form.
- You have had at least one visit with your doctor during the study period.
- You do not have other types of angioedema, such as acquired angioedema, drug-induced angioedema, or HAE with normal C1 inhibitor levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study looks at thoughts of suicide in people with hereditary angioedema (HAE), a condition that causes sudden swelling. It aims to understand if and how these thoughts may be linked to the condition, so that better support can be offered.
This study looks at how well Takhzyro (lanadelumab) works for people with a specific type of hereditary angioedema (HAE) that is caused by a C1 inhibitor deficiency. It is for teenagers and adults who have already been taking Takhzyro for at least 6 months.
This study looks for genetic changes that may explain hereditary angioedema (HAE) and how C1 inhibitor (C1INH) works. Your participation may help researchers better understand what causes symptoms and who is affected.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.